Skip to content

About
Clinical Trials
Science
Our News
Contact Us
- Contact
- Careers

Menu

About
Clinical Trials
Science
Our News
Contact Us
- Contact
- Careers

Press Releases

Newsroom

Press Releases
Media

2024

Tvardi Therapeutics to Present at the 8th Annual IPF Summit

August 14, 2024

Tvardi Therapeutics to Participate at the 2024 BTIG Virtual Biotechnology Conference

July 31, 2024

Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors

March 25, 2024

Tvardi Therapeutics to Participate at the Cowen 44th Annual Health Care Conference

March 1, 2024

Tvardi Therapeutics Announces Presentation of REVERT_{LIVER CANCER} Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium

January 18, 2024

2023

Tvardi Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference

November 21, 2023

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Idiopathic Pulmonary Fibrosis Trial using TTI-101, a Novel STAT3 Inhibitor

August 31, 2023

Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor

June 22, 2023

Tvardi Therapeutics Announces Presentation of Data from the Phase 1 Trial of TTI-101, a STAT3 Inhibitor, in Advanced Solid Tumors at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

May 25, 2023

Tvardi Therapeutics to Participate at the Cowen 43rd Annual Health Care Conference

February 28, 2023

Tvardi Therapeutics Appoints John Kauh, M.D. as Chief Medical Officer

February 7, 2023

2022

Tvardi Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

November 29, 2022

FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma

October 19, 2022

Tvardi Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

September 8, 2022

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis

May 26, 2022

Tvardi Therapeutics to Participate in Morgan Stanley Private Company Biotech Corporate Access Day

April 28, 2022

Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma

April 21, 2022

2021

Fierce Biotech Names Tvardi Therapeutics as One of its “Fierce 15” Biotech Companies of 2021

September 27, 2021

Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs

June 23, 2021

Tvardi Therapeutics Appoints Michael Wyzga, Former CFO of Genzyme, to Board of Directors

March 11, 2021

Tvardi Therapeutics Appoints Sujal Shah to Board of Directors

January 28, 2021

2020

Tvardi Therapeutics Awarded “Most Promising” Company at the 2020 Texas Life Science Forum

November 12, 2020

Tvardi’s TTI-101 Receives $5 Million in Funding to Support Clinical Trials and Translational Research

July 24, 2020

2018

Tvardi Therapeutics names Imran Alibhai Chief Executive Officer

December 12, 2018

Tvardi’s Scientific Advisory Board Member, Dr. Jim Allison, Wins Nobel

October 1, 2018

Tvardi Announces Series A Financing

September 20, 2018

Home
About
Clinical Trials
Science
Our News
Contact Us
FCOI
Privacy Policy
Terms of Use

Home
About
Clinical Trials
Science
Our News
Contact Us
FCOI
Privacy Policy
Terms of Use

Linkedin Twitter

Scroll to Top

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and Terms of Use.

Accept & Close